# Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

> **NCT06811844** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 208 (estimated)

## Conditions studied

- Nasopharyngeal Neoplasms
- PD-1 Inhibitor
- Induction Therapy
- Complete Response
- Chemotherapy

## Interventions

- **DRUG:** Two-cycle induction chemotherapy + immunotherapy
- **DRUG:** Three-cycle induction chemotherapy + immunotherapy

## Key facts

- **NCT ID:** NCT06811844
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06811844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06811844, "Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06811844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*